SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis
SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis
BACKGROUND: Allergy immunotherapy is a treatment option for allergic rhinoconjunctivitis (ARC). It is unique compared with pharmacotherapy in that it modifies the immunologic pathways that elicit an allergic response. The SQ Timothy grass sublingual immunotherapy (SLIT) tablet is approved in North America and throughout Europe for the treatment of adults and children (greater than or equal to 5 years old) with grass pollen-induced ARC.
OBJECTIVE: The clinical evidence for the use of SQ grass SLIT-tablet as a disease-modifying treatment for grass pollen ARC is discussed in this review.
METHODS: The review included the suitability of SQ grass SLIT-tablet for patients with clinically relevant symptoms to multiple Pooideae grass species, single-season efficacy, safety, adherence, coseasonal initiation, and cost-effectiveness. The data from the long-term SQ grass SLIT-tablet clinical trial that evaluated a clinical effect 2 years after a continuous 3-year treatment period were presented in the context of regulatory criteria that define a clinically meaningful effect.
RESULTS: This trial demonstrated that the clinical effect of the SQ grass SLIT-tablet is maintained, which is also supported by the immunologic findings.
CONCLUSION: Therefore, the SQ grass SLIT-tablet has an indication as a disease-modifying therapy in Europe, and a sustained effect is recognized in the United States.
92-104
Dahl, R.
ca31be56-52e7-433a-b60e-25e5aba41f78
Roberts, G.
ea00db4e-84e7-4b39-8273-9b71dbd7e2f3
de Blic, J.
4bcc2551-bad2-4ee1-a9e7-b1541aa36ec9
Canonica, G.W.
b9d303f8-7c7d-4e9f-8b51-a92374d98ea0
Kleine-Tebbe, J.
37b07cf7-30c3-4c64-9429-d302e05bd008
Nolte, H.
680b2bcd-0507-40d4-b17e-27766e417b6c
Lawton, S.
40363bea-7500-48a6-94f0-de7116143c41
Nelson, H.S.
28fa9639-5453-4589-a191-e2c32bb4490a
March 2016
Dahl, R.
ca31be56-52e7-433a-b60e-25e5aba41f78
Roberts, G.
ea00db4e-84e7-4b39-8273-9b71dbd7e2f3
de Blic, J.
4bcc2551-bad2-4ee1-a9e7-b1541aa36ec9
Canonica, G.W.
b9d303f8-7c7d-4e9f-8b51-a92374d98ea0
Kleine-Tebbe, J.
37b07cf7-30c3-4c64-9429-d302e05bd008
Nolte, H.
680b2bcd-0507-40d4-b17e-27766e417b6c
Lawton, S.
40363bea-7500-48a6-94f0-de7116143c41
Nelson, H.S.
28fa9639-5453-4589-a191-e2c32bb4490a
Dahl, R., Roberts, G., de Blic, J., Canonica, G.W., Kleine-Tebbe, J., Nolte, H., Lawton, S. and Nelson, H.S.
(2016)
SQ grass sublingual allergy immunotherapy tablet for disease-modifying treatment of grass pollen allergic rhinoconjunctivitis.
Allergy and Asthma Proceedings, 37 (2), .
(doi:10.2500/aap.2016.37.3937).
(PMID:26802643)
Abstract
BACKGROUND: Allergy immunotherapy is a treatment option for allergic rhinoconjunctivitis (ARC). It is unique compared with pharmacotherapy in that it modifies the immunologic pathways that elicit an allergic response. The SQ Timothy grass sublingual immunotherapy (SLIT) tablet is approved in North America and throughout Europe for the treatment of adults and children (greater than or equal to 5 years old) with grass pollen-induced ARC.
OBJECTIVE: The clinical evidence for the use of SQ grass SLIT-tablet as a disease-modifying treatment for grass pollen ARC is discussed in this review.
METHODS: The review included the suitability of SQ grass SLIT-tablet for patients with clinically relevant symptoms to multiple Pooideae grass species, single-season efficacy, safety, adherence, coseasonal initiation, and cost-effectiveness. The data from the long-term SQ grass SLIT-tablet clinical trial that evaluated a clinical effect 2 years after a continuous 3-year treatment period were presented in the context of regulatory criteria that define a clinically meaningful effect.
RESULTS: This trial demonstrated that the clinical effect of the SQ grass SLIT-tablet is maintained, which is also supported by the immunologic findings.
CONCLUSION: Therefore, the SQ grass SLIT-tablet has an indication as a disease-modifying therapy in Europe, and a sustained effect is recognized in the United States.
This record has no associated files available for download.
More information
e-pub ahead of print date: 21 January 2016
Published date: March 2016
Organisations:
Human Development & Health
Identifiers
Local EPrints ID: 388714
URI: http://eprints.soton.ac.uk/id/eprint/388714
ISSN: 1088-5412
PURE UUID: 748eaab4-579f-46fb-988e-e6935e23e2a7
Catalogue record
Date deposited: 02 Mar 2016 12:08
Last modified: 15 Mar 2024 03:22
Export record
Altmetrics
Contributors
Author:
R. Dahl
Author:
J. de Blic
Author:
G.W. Canonica
Author:
J. Kleine-Tebbe
Author:
H. Nolte
Author:
S. Lawton
Author:
H.S. Nelson
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics